Expanded Discussion of What’s New in the Guideline S43
Expert Reviewer Relationships With Industry and Other Entities S32Īppendix 5. Author Relationships With Industry and Other Entities (Relevant) S28Īppendix 2. Evidence Gaps and Future Research Needs S24Īppendix 1. Sex and Racial and Ethnic Subgroups S23ĩ. Selected Clinical and Population Subgroups S23ħ.1. Insufficient Response to Statin Therapy S21Ħ.3.2 Nonstatins Added to Statins or in Statin-Intolerant Individuals S22ħ. Managing Statin Therapy: Recommendations S21Ħ.3. Risk Assessment in Primary Prevention S17Ħ. Primary Prevention in Individuals Without Diabetes and With LDL-C 70 to 189 mg/dL S16Ĥ.7. Primary Prevention in Individuals With Diabetes S16Ĥ.6. Primary Prevention in Individuals ≥21 Years of Age With LDL-C ≥190 mg/dL S14Ĥ.5. LDL-C and Non–HDL-C Treatment Goals S12Ĥ.4. Intensity of Statin Therapy in Primary and Secondary Prevention S12Ĥ.2. CQ3: Efficacy and Safety of Cholesterol-Lowering Medications S10Ĥ.1. CQ2: LDL-C and Non–HDL-C Goals in Primary Prevention S10ģ.1.3. CQ1: LDL-C and Non–HDL-C Goals in Secondary Prevention S10ģ.1.2. Critical Questions and Conclusions S10ģ.1.1. Lifestyle as the Foundation for ASCVD Risk-Reduction Efforts S6ģ. Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2Ģ.1. Customer Service and Ordering Information.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
